Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H14N2O2 |
Molecular Weight | 146.1876 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCCC[C@H](N)C(O)=O
InChI
InChIKey=KDXKERNSBIXSRK-YFKPBYRVSA-N
InChI=1S/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1
DescriptionSources: https://www.nap.edu/read/10490/chapter/12Curator's Comment: description was created based on several sources, including
https://www.drugs.com/npp/lysine.html | https://www.ncbi.nlm.nih.gov/pubmed/26252373
Sources: https://www.nap.edu/read/10490/chapter/12
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/npp/lysine.html | https://www.ncbi.nlm.nih.gov/pubmed/26252373
Lysing is an essential basic amino-acid encoded by codone AAA and AAG, and used in the biosynthesis of proteins. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken. In a clinical study lysine supplements was found to be an effective for reduction of occurrence, severity and healing time for recurrent HSV infection, however Cochrane Review concluded that the evidence is insufficient. Lysine was investigated for improving anxiety, ameliorating angina prectoris. Lysine acetylsalicylate has been used to treat pain and to detoxify the body after heroin use. Lysine clonixinate has been used for its analgesic properties for the treatment of migraine headaches and other painful conditions. However, limited clinical trials exist for these conditions.
CNS Activity
Originator
Sources: https://www.drugs.com/npp/lysine.html
Curator's Comment: Lysine was first isolated from casein (a milk phosphoprotein) in 1889 by the German dentist Heinrich Drechsel
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1875 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28103616 |
|||
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8587651 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | L-LYSINE MONOHYDRATE Approved UseLysine has been studied for the prevention and treatment of herpes infections and cold sores. |
|||
Primary | L-LYSINE MONOHYDRATE Approved UseLysine supplements may relieve effort-related angina pectoris. |
|||
Sources: https://www.drugs.com/npp/lysine.html |
Primary | L-LYSINE MONOHYDRATE Approved UseLysine increases the intestinal absorption and reduces the renal elimination of calcium. |
||
Sources: https://www.drugs.com/npp/lysine.html |
Primary | L-LYSINE MONOHYDRATE Approved UseLysine is believed to exert anxiolytic effects by acting as a partial serotonin receptor 4 antagonist and as a partial benzodiazepine agonist |
||
Palliative | L-LYSINE MONOHYDRATE Approved UseLysine acetylsalicylate has been used to detoxify the body after heroin use. |
|||
Primary | NEOPROFEN Approved UseNeoProfen is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA. Launch Date2006 |
PubMed
Title | Date | PubMed |
---|---|---|
The antioxidant system beta-D(+) glucose-glucose oxidase-catalase: tests for pyrogenicity and antigenicity. | 2001 |
|
The fermentative production of L-lysine as an animal feed additive. | 2001 Apr |
|
Effect of the degree of fatty acid unsaturation of rat heart mitochondria on their rates of H2O2 production and lipid and protein oxidative damage. | 2001 Apr 15 |
|
The number of morphological synapses between neurons does not predict the strength of their physiological synaptic interactions: a study of dendrites in the nematode Ascaris suum. | 2001 Apr 16 |
|
Properties of microtubules assembled from mammalian tubulin synthesized in Escherichia coli. | 2001 Apr 17 |
|
Peflin and ALG-2, members of the penta-EF-hand protein family, form a heterodimer that dissociates in a Ca2+-dependent manner. | 2001 Apr 27 |
|
Biochemical and functional characterization of a molecule expressed by a subset of thymic medullary epithelial cells. | 2001 Feb |
|
Endotoxin, endotoxin-neutralizing-capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease. | 2001 Feb |
|
Hydrolysed protein accelerates the gastrointestinal transport of formula in preterm infants. | 2001 Feb |
|
Combination of HPLC and solid-phase binding assay for isolation and purification of MHC class I and associated peptides using a bladder tumour cell line. | 2001 Feb |
|
Affinity purification of Csk protein tyrosine kinase based on its catalytic requirement for divalent metal cations. | 2001 Feb |
|
Characterization of the lipopolysaccharide of Yersinia pestis. | 2001 Feb |
|
Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. | 2001 Feb |
|
Increased L-arginine uptake and inducible nitric oxide synthase activity in aortas of rats with heart failure. | 2001 Feb |
|
The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. | 2001 Feb |
|
Identification of a candidate integrin-fraction associated with the activated form of the PDGF-receptor. | 2001 Feb 23 |
|
Purification and biophysical characterization of a minimal functional domain and of an N-terminal Zn2+-binding fragment from the human papillomavirus type 16 E6 protein. | 2001 Feb 6 |
|
Uptake and accumulation of exogenous docosahexaenoic acid by Chlorella. | 2001 Jan |
|
Endotoxemia and acute-phase proteins in major abdominal surgery. | 2001 Jan |
|
Influence of lysates of the salivary glands of Lutzomyia longipalpis on the development of a Leishmania-major-like parasite in the skin of the golden hamster. | 2001 Jan |
|
ESR detection of intraphagosomal superoxide in polymorphonuclear leukocytes using 5-(diethoxyphosphoryl)-5-methyl-l-pyrroline-N-oxide. | 2001 Jan |
|
Increased stability of nucleophosmin/B23 in anti-apoptotic effect of ras during serum deprivation. | 2001 Jan |
|
A Mycobacterium smegmatis gyrase B specific monoclonal antibody reveals association of gyrase A and B subunits in the cell. | 2001 Jan 1 |
|
Mechanism of release of urinary Tamm-Horsfall glycoprotein from the kidney GPI-anchored counterpart. | 2001 Jan 12 |
|
Acceleration of thrombomodulin gene transcription by retinoic acid: retinoic acid receptors and Sp1 regulate the promoter activity through interactions with two different sequences in the 5'-flanking region of human gene. | 2001 Jan 26 |
|
Hsp90 regulates p50(cdc37) function during the biogenesis of the activeconformation of the heme-regulated eIF2 alpha kinase. | 2001 Jan 5 |
|
Purification of recombinant green fluorescent protein using chromatofocusing with a pH gradient composed of multiple stepwise fronts. | 2001 Jan-Feb |
|
The function of interdomain interactions in controlling nucleotide exchange rates in transducin. | 2001 Jun 29 |
|
Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. | 2001 Mar |
|
Inositol phosphates from barley low-phytate grain mutants analysed by metal-dye detection HPLC and NMR. | 2001 Mar 1 |
|
Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. | 2001 Mar 15 |
|
High pressure increases bactericidal activity and spectrum of lactoferrin, lactoferricin and nisin. | 2001 Mar 20 |
|
Inhibition of cytosolic phospholipase A2 by annexin I. Specific interaction model and mapping of the interaction site. | 2001 May 11 |
|
CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. | 2001 May 25 |
|
The heme-regulated eukaryotic initiation factor 2alpha kinase. A potential regulatory target for control of protein synthesis by diffusible gases. | 2001 May 4 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.nap.edu/read/10490/chapter/12
Lysin is an essential amino-acid. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28103616
In the in vitro study of herpes simplex virus (HSV) growth in tissue culture, arginine deficiency suppressed HSV growth. Maximum herpes growth (as measured by plaques counting) was observed in flasks, containing 10-20 ug/ml of arginine. The addition of 50 ug/ml of lysine to the flasks containing 2.5 and 5.0 ug/ml of arginine reduced the number of viable plaque-forming units (PFU) from 3300 and 48800 to less than 10.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
32256-0
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
56955-8
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
22651-4
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
15140-7
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
WHO-VATC |
QB05XB03
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
13375-1
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
2587-4
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
13769-5
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
2586-6
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
47689-5
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
20650-8
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
47693-7
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
47694-5
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
22713-2
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
47692-9
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
25952-3
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
47695-2
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
WHO-ATC |
B05XB03
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
44335-8
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
2585-8
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
30048-3
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
13404-9
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
15136-5
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
55935-1
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
88018-7
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
DSLD |
172 (Number of products:1388)
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
27333-4
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
WHO-VATC |
QA12AA09
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
17230-4
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
27107-2
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
25464-9
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
JECFA EVALUATION |
1439
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
32255-2
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
2584-1
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
22679-5
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
CFR |
21 CFR 310.537
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
27304-5
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
25953-1
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
47690-3
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
LOINC |
47691-1
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
||
|
NCI_THESAURUS |
C68442
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2108
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
6166
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
DB00123
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
m6967
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB36688
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
200-294-2
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
133538
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
1427
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
SUB08629MIG
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
K3Z4F929H6
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
100000091077
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
5962
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
DTXSID6023232
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
56-87-1
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
K3Z4F929H6
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
18019
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL8085
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
CONCEPT | Dietary Supplement | ||
|
1622
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
29967
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
C29171
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
LYSINE
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
6536
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | RxNorm | ||
|
32551
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
D008239
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY | |||
|
25094
Created by
admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)